Kidney cancer trials in China

In China 117 Also abroad 486

117 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 1Not yet taking people in China
UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma
Where
Zhengzhou
Age
18 years to 75 years
People
21
Run by
UTC Therapeutics Inc.
See details and how to joinNCT07500805
No phaseNot yet taking people in China
Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma
Where
Jinan
Age
18 years and over
People
43
Run by
Qilu Hospital of Shandong University
See details and how to joinNCT07500831
Phase 2Not yet taking people in China
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
Where
Shanghai
Age
18 years to 75 years
People
230
Run by
Zhejiang Haichang Biotech Co., Ltd.
See details and how to joinNCT07494435
No phaseNot yet taking people in China
Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy
Where
Guangzhou
Age
18 years to 80 years
People
174
Run by
Sun Yat-sen University
See details and how to joinNCT07497958
Phase 1/2Taking people
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Where
Beijing, Bengbu, Changchun, Dalian, Dongguan, Fuzhou, Guangzhou, Haerbin, Hangzhou, Jinan, Kunming, Nanchang, Shanghai, Shenyang, Taiyuan, Tianjin, Ürümqi, Xiamen, Zhengzhou, Zhuhai
Age
18 years and over
People
170
Run by
3D Medicines (Sichuan) Co., Ltd.
See details and how to joinNCT05024214
Phase 2Enrolling by invitation
Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study
Where
Guangzhou
Age
18 years to 75 years
People
60
Run by
Sun Yat-sen University
See details and how to joinNCT07488572
No phaseNot yet taking people in China
A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly Patients After Urological Surgery
Where
Hangzhou
Age
60 years and over
People
220
Run by
Zhejiang University
See details and how to joinNCT07480044
Phase 3Taking people
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
Where
Beijing, Guangzhou, Hefei, Shanghai, Sichuan, Tianjin, Zhengzhou
Age
18 years to 80 years
People
298
Run by
ZHOU FANGJIAN
See details and how to joinNCT05738694
No phaseTaking people
68Ga-PSMA PET in the Renal Cell Carcinoma
Where
Lanzhou, Weinan, Xi'an, Xianyang, Xining, Yan’an, Yinchuan
Age
18 years to 90 years
People
300
Run by
Xijing Hospital
See details and how to joinNCT04987086
Phase 1/2Taking people
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Where
Beijing
People
83
Run by
Essen Biotech
See details and how to joinNCT07410676
Phase 2Taking people
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Where
Guangzhou
Age
18 years to 80 years
People
25
Run by
Sun Yat-sen University
See details and how to joinNCT07389629
Phase 2Taking people
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
Where
Guangzhou
Age
18 years to 85 years
People
21
Run by
Sun Yat-sen University
See details and how to joinNCT07386158
No phaseTaking people
SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
Where
Beijing
Age
18 years to 85 years
People
300
Run by
Peking University First Hospital
See details and how to joinNCT06583070
Phase 3Taking people
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
Where
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Shanghai, Wenzhou, Wuhan
Age
18 years and over
People
252
Run by
Sun Yat-sen University
See details and how to joinNCT06726421
No phaseNot yet taking people in China
A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC)
Where
Tianjin
Age
18 years to 90 years
People
860
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07324876
No phaseTaking people
The Cold Ischemia Robot-assisted Partial Nephrectomy
Where
Guangzhou
Age
18 years to 80 years
People
310
Run by
Sun Yat-sen University
See details and how to joinNCT07326280
Phase 2Taking people
CD70-targeted immunoPET Imaging of Kidney Cancer
Where
Shanghai
Age
18 years to 80 years
People
300
Run by
RenJi Hospital
See details and how to joinNCT06680089
No phaseNot yet taking people in China
AI for Renal Tumors Using Non-Contrast CT
Where
Shanghai
Age
18 years to 80 years
People
10,000
Run by
Fudan University
See details and how to joinNCT07304492
No phaseTaking people
Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma
Where
Wuhan
Age
18 years and over
People
66
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07301827
No phaseTaking people
Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy
Where
Nanjing
Age
18 years and over
People
285
Run by
Jinling Hospital, China
See details and how to joinNCT07294859
No phaseTaking people
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Where
Nanjing
People
450
Run by
Jinling Hospital, China
See details and how to joinNCT05917106
No phaseTaking people
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Where
Nanjing
Age
18 years to 80 years
People
39
Run by
Jinling Hospital, China
See details and how to joinNCT06676527
Phase 2Taking people
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Where
Shanghai
Age
18 years to 75 years
People
260
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT06962787
Phase 2Not yet taking people in China
A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy
Where
Shanghai
Age
18 years to 75 years
People
31
Run by
RenJi Hospital
See details and how to joinNCT06730932
Phase 2Taking people
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Where
Tianjin
Age
18 years and over
People
40
Run by
Tianjin Medical University Second Hospital
See details and how to joinNCT07172386